Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Payables (2019 - 2025)

Keros Therapeutics filings provide 7 years of Payables readings, the most recent being $2.0 million for Q4 2025.

  • On a quarterly basis, Payables fell 57.26% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 57.26% decrease, with the full-year FY2025 number at $2.0 million, down 57.26% from a year prior.
  • Payables hit $2.0 million in Q4 2025 for Keros Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.7 million in Q2 2022 to a low of $1.4 million in Q2 2021.
  • Median Payables over the past 5 years was $4.0 million (2023), compared with a mean of $4.1 million.
  • Biggest five-year swings in Payables: plummeted 71.72% in 2021 and later skyrocketed 458.31% in 2022.
  • Keros Therapeutics' Payables stood at $3.6 million in 2021, then dropped by 8.4% to $3.3 million in 2022, then soared by 63.22% to $5.4 million in 2023, then decreased by 15.56% to $4.6 million in 2024, then tumbled by 57.26% to $2.0 million in 2025.
  • The last three reported values for Payables were $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $5.3 million (Q2 2025) per Business Quant data.